Ardelyx Company Profile (NASDAQ:ARDX)

About Ardelyx

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDX
  • CUSIP:
Key Metrics:
  • Previous Close: $13.15
  • 50 Day Moving Average: $12.81
  • 200 Day Moving Average: $12.78
  • 52-Week Range: $47,301,000.00 - $6.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.48
  • P/E Growth: -0.18
  • Market Cap: $617.29B
  • Outstanding Shares: 47,301,000
  • Beta: 0.17
Profitability:
  • Return on Equity: -61.31%
  • Return on Assets: -56.54%
Debt:
  • Current Ratio: 13.28%
  • Quick Ratio: 13.28%
Additional Links:
Companies Related to Ardelyx:

Analyst Ratings

Consensus Ratings for Ardelyx (NASDAQ:ARDX) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.57 (49.97% upside)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017WedbushReiterated RatingOutperform$24.00View Rating Details
11/20/2016Leerink SwannSet Price TargetBuy$18.00View Rating Details
8/10/2016Citigroup Inc.Lower Price TargetBuy$14.00 -> $13.00View Rating Details
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
3/31/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$21.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details
12/18/2015BTIG ResearchInitiated CoverageBuy$33.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Ardelyx (NASDAQ:ARDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2017        
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)ViewN/AView Earnings Details
2/25/2015($0.06)($0.21)ViewListenView Earnings Details
8/7/2014$1.83$0.44ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ardelyx (NASDAQ:ARDX)
Current Year EPS Consensus Estimate: $-2.78 EPS
Next Year EPS Consensus Estimate: $-2.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.73)($0.74)
Q2 20162($0.67)($0.66)($0.67)
Q3 20162($0.78)($0.62)($0.70)
Q4 20162($0.66)($0.60)($0.63)
Q1 20171($0.67)($0.67)($0.67)
Q2 20171($0.72)($0.72)($0.72)
Q3 20171($0.78)($0.78)($0.78)
Q4 20171$0.78$0.78$0.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ardelyx (NASDAQ:ARDX)
Insider Ownership Percentage: 15.46%
Institutional Ownership Percentage: 81.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.00View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.00View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ardelyx (NASDAQ:ARDX)
DateHeadline
finance.yahoo.com logoArdelyx reports 4Q loss - Yahoo Finance - Yahoo Finance (NASDAQ:ARDX)
finance.yahoo.com - February 18 at 3:34 PM
News IconBrokers Change Their Target Price On Ardelyx, Inc. (ARDX) (NASDAQ:ARDX)
oakridgeobserver.com - February 18 at 9:41 AM
News IconArdelyx, Inc. (ARDX) Stock Rating Reaffirmed by Wedbush (NASDAQ:ARDX)
mundoaguaysaneamiento.net - February 18 at 9:41 AM
News IconArdelyx, Inc. (ARDX) Given Outperform Rating at Wedbush (NASDAQ:ARDX)
hoyentv.com - February 18 at 9:41 AM
4-traders.com logoArdelyx : reports 4Q loss (NASDAQ:ARDX)
www.4-traders.com - February 17 at 6:32 PM
us.rd.yahoo.com logoBlog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease (NASDAQ:ARDX)
us.rd.yahoo.com - February 17 at 6:32 PM
us.rd.yahoo.com logoArdelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ARDX)
us.rd.yahoo.com - February 17 at 6:32 PM
sg.finance.yahoo.com logoArdelyx reports 4Q loss (NASDAQ:ARDX)
sg.finance.yahoo.com - February 17 at 6:32 PM
biz.yahoo.com logoARDELYX, INC. Files SEC form 10-K, Annual Report (NASDAQ:ARDX)
biz.yahoo.com - February 17 at 6:32 PM
4-traders.com logoArdelyx reports Phase 3 trial of Tenapanor a success - Ardelyx, Inc. (NASDAQ :.. (NASDAQ:ARDX)
www.4-traders.com - February 16 at 8:41 PM
proactiveinvestors.co.uk logoArdelyx reports Phase 3 trial of Tenapanor a success (NASDAQ:ARDX)
www.proactiveinvestors.co.uk - February 16 at 8:41 PM
proactiveinvestors.co.uk logoArdelyx reports Phase 3 trial of Tenapanor a success (NASDAQ:ARDX)
www.proactiveinvestors.co.uk - February 16 at 8:41 PM
us.rd.yahoo.com logoArdelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease (NASDAQ:ARDX)
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logoArdelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease (NASDAQ:ARDX)
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logo6:31 am Ardelyx reports its Phase 3 trial evaluating tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint and was generally well-tolerated (NASDAQ:ARDX)
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logo6:31 am Ardelyx reports its Phase 3 trial evaluating tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint and was generally well-tolerated (NASDAQ:ARDX)
us.rd.yahoo.com - February 16 at 8:41 PM
News IconIs The Sell-Side Predicting That Ardelyx, Inc. (NASDAQ:ARDX) Will Move Higher? - Winfield Review (NASDAQ:ARDX)
winfieldreview.com - February 16 at 3:41 PM
marketexclusive.com logoHere's What The Latest Ardelyx Inc (NASDAQ:ARDX) Data Means For The Company Going Forward - Market Exclusive (NASDAQ:ARDX)
marketexclusive.com - February 16 at 3:41 PM
insidermonkey.com logoHere’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward (NASDAQ:ARDX)
www.insidermonkey.com - February 16 at 3:41 PM
rttnews.com logoARDX Kidney Drug Passes Phase 3 Study, EDIT Up On CRISPR News, FDA Nod For VRX - RTT News (NASDAQ:ARDX)
www.rttnews.com - February 16 at 8:32 AM
News IconAre Analysts Optimistic About Where Ardelyx, Inc. (NASDAQ:ARDX) is Heading? - Winfield Review (NASDAQ:ARDX)
winfieldreview.com - February 16 at 8:32 AM
investopedia.com logoArdelyx Says Tenapanor Did Well In Study (ARDX) - Investopedia (NASDAQ:ARDX)
www.investopedia.com - February 16 at 8:32 AM
biz.yahoo.com logoARDELYX, INC. Files SEC form 8-K, Other Events (NASDAQ:ARDX)
biz.yahoo.com - February 16 at 8:32 AM
thestreet.com logoBiotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co. (NASDAQ:ARDX)
www.thestreet.com - February 16 at 8:32 AM
investopedia.com logoArdelyx Says Tenapanor Did Well In Phase 3 Study (NASDAQ:ARDX)
www.investopedia.com - February 16 at 8:32 AM
News IconStock Spotlight: Zooming in on Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Piedmont Register (NASDAQ:ARDX)
piedmontregister.com - February 14 at 9:15 PM
News IconArdelyx, Inc. NASDAQ:ARDX Sees High Volatility in Session - Aiken Advocate (NASDAQ:ARDX)
aikenadvocate.com - February 13 at 4:05 PM
News IconStock Spotlight: Zooming in on Shares of Ardelyx, Inc. (NASDAQ:ARDX) - The Tribune (NASDAQ:ARDX)
lakecitytribune.com - January 25 at 3:42 PM
News IconArdelyx, Inc. (ARDX) Valuation According To Analysts - UK Market ... - UK Market News (NASDAQ:ARDX)
www.ukmarketnews.co.uk - January 25 at 1:59 AM
News IconMarket Update: Watching Increased Volatility on Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Wall Street Beacon (NASDAQ:ARDX)
wsbeacon.com - January 24 at 3:55 PM
News IconRSI Review on Shares of Ardelyx Inc. (ARDX) - Sherwood Daily (NASDAQ:ARDX)
sherwooddaily.com - January 20 at 4:38 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Ardelyx, Inc. (NASDAQ:ARDX) - Wall Street Beacon (NASDAQ:ARDX)
wsbeacon.com - January 20 at 4:38 PM
News IconArdelyx Inc. (NASDAQ:ARDX) Is An In Demand Biotech - Small Cap Exclusive (press release) (NASDAQ:ARDX)
smallcapexclusive.com - January 19 at 7:13 PM
News IconShould You Buy Or Sell Ardelyx, Inc. (ARDX) On Analyst Concensus? - NewsDen (NASDAQ:ARDX)
newsden.net - January 18 at 9:16 PM
News IconWith Profitability At The Forefront, Is This Stock a Top Pick: Ardelyx, Inc. (NASDAQ:ARDX) - Wall Street Beacon (NASDAQ:ARDX)
wsbeacon.com - January 16 at 8:37 PM
News IconWill The Needle Move For Ardelyx, Inc. (NASDAQ:ARDX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ARDX)
wsbeacon.com - January 16 at 8:37 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Ardelyx, Inc. (NASDAQ:ARDX) - Wall Street Beacon (NASDAQ:ARDX)
wsbeacon.com - January 14 at 3:36 PM
biz.yahoo.com logoARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial (NASDAQ:ARDX)
biz.yahoo.com - January 9 at 3:49 PM
marketexclusive.com logoAnalyst Activity – Wedbush Reiterates Outperform on Ardelyx ... - Market Exclusive (NASDAQ:ARDX)
marketexclusive.com - January 8 at 3:34 PM
marketexclusive.com logoAnalyst Activity – Wedbush Reiterates Outperform on Ardelyx (NASDAQ:ARDX) (NASDAQ:ARDX)
marketexclusive.com - January 6 at 8:45 PM
streetinsider.com logoArdelyx (ARDX): KOL Call Increases Belief of Tenapanor Approvability - Wedbush (NASDAQ:ARDX)
www.streetinsider.com - January 6 at 3:43 PM
streetinsider.com logoArdelyx (ARDX) Initiates Phase 3, and Onset-of-Action Trials of RDX7675 in Hyperkalemia (NASDAQ:ARDX)
www.streetinsider.com - January 3 at 9:13 PM
us.rd.yahoo.com logoArdelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference (NASDAQ:ARDX)
us.rd.yahoo.com - January 3 at 9:13 PM
News IconArdelyx initiates two clinical trials to evaluate new treatment for hyperkalemia - News-Medical.net (NASDAQ:ARDX)
www.news-medical.net - January 3 at 4:12 PM
streetinsider.com logoArdelyx (ARDX) Initiates Phase 3, and Onset-of-Action Trials of RDX7675 in Hyperkalemia - StreetInsider.com (NASDAQ:ARDX)
www.streetinsider.com - January 3 at 8:29 AM
finance.yahoo.com logo6:36 am Ardelyx initiates a Phase 3 clinical trial and an onset-of-action clinical trial evaluating RDX7675 in patients with hyperkalemia; expects to report data from the onset-of-action study in 1H17 (NASDAQ:ARDX)
finance.yahoo.com - January 3 at 8:29 AM
publicnow.com logoArdelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia (NASDAQ:ARDX)
www.publicnow.com - January 3 at 8:29 AM
News IconThe SVP, Drug Development of Ardelyx (NASDAQ: ARDX) is Selling Shares - Analyst Ratings (NASDAQ:ARDX)
www.analystratings.com - December 21 at 1:53 AM
News IconVC Score In Focus for Ardelyx, Inc. (NASDAQ:ARDX) - Marion Business Daily (NASDAQ:ARDX)
marionbusinessdaily.com - December 20 at 8:37 AM
News IconFCF Score Check on Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Marion Business Daily (NASDAQ:ARDX)
marionbusinessdaily.com - December 18 at 8:40 PM

Social

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2017?

7 brokerages have issued 12 month price objectives for Ardelyx's stock. Their forecasts range from $13.00 to $24.00. On average, they expect Ardelyx's share price to reach $19.57 in the next twelve months.

When will Ardelyx announce their earnings?

Ardelyx is scheduled to release their next quarterly earnings announcement on Thursday, March, 2nd 2017.

Who owns Ardelyx stock?

Ardelyx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Future Fund Board of Guardians (7.30%), FMR LLC (7.03%), Perceptive Advisors LLC (3.88%), EcoR1 Capital LLC (2.77%), State Street Corp (0.98%) and Deerfield Management Co. (0.79%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Enterprise Associates 12 New, Gordon Ringold, Jeffrey W Jacobs, Mark Kaufmann, Michael Raab, Nea 15 Gp, Llc and Peter G Schultz.

Who sold Ardelyx stock? Who is selling Ardelyx stock?

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Deerfield Management Co. and Wall Street Associates. Company insiders that have sold Ardelyx stock in the last year include David P Rosenbaum, Elizabeth A Grammer and Jeffrey W Jacobs.

Who bought Ardelyx stock? Who is buying Ardelyx stock?

Ardelyx's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Marshall Wace LLP, Axiom International Investors LLC DE, State Street Corp, Renaissance Technologies LLC, Russell Investments Group Ltd., Metropolitan Life Insurance Co. NY and Acuta Capital Partners LLC. Company insiders that have bought Ardelyx stock in the last two years include Enterprise Associates 12 New, Gordon Ringold, Nea 15 Gp, Llc and Peter G Schultz.

How do I buy Ardelyx stock?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ardelyx stock cost?

One share of Ardelyx stock can currently be purchased for approximately $13.05.

Ardelyx (NASDAQ:ARDX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Earnings History Chart

Earnings by Quarter for Ardelyx (NASDAQ:ARDX)

Dividend History Chart

Dividend Payments by Quarter for Ardelyx (NASDAQ:ARDX)

Last Updated on 2/19/2017 by MarketBeat.com Staff